We previously demonstrated that systemic administration of adenovirus serotype 35 (Ad35) vectors to mice does not mediate efficient transduction in organs, probably because expression of the mouse analog of the subgroup B Ad receptor, human CD46 (membrane cofactor protein), is limited to the testis. Here, we describe the in vitro and in vivo transduction characteristics of Ad35 vectors by using homozygous and hemizygous human CD46-transgenic (CD46TG) mice, which ubiquitously express human CD46. An Ad35 vector more efficiently transduced the primary dendritic cells and macrophages prepared from CD46TG mice than those from wild-type mice. In vivo transduction experiments demonstrated that CD46TG mice are more susceptible to Ad35 vector-mediated in vivo transduction than are wild-type mice. In particular, homozygous CD46TG mice, which express higher levels of CD46 in the organs than hemizygous CD46TG mice, tend to exhibit higher transduction efficiencies after intraperitoneal administration than hemizygous CD46TG mice. Intraperitoneal administration of Ad35 vectors resulted in efficient transduction into the mesothelial cells of the peritoneal organs in homozygous CD46TG mice. These results indicate that an Ad35 vector recognizes human CD46 as a cellular receptor in CD46TG mice. However, the in vivo transduction efficiencies of Ad35 vectors in CD46TG mice are much lower than those of conventional Ad5 vectors in wild-type mice.
The human adenoviruses (Ads) comprise a group of 51 serologically distinct viruses. 1, 2 Among them, Ad vectors widely used for gene therapy are based on Ad serotype 5 (Ad5), which belongs to subgroup C. Adenovirus serotype 5 vectors have several attractive features as gene delivery vehicles; for example, they have noteworthy in vivo transduction efficiency and transduction ability into both proliferating and non-proliferating cells. In addition, Ad5 vectors can be grown to high titer, and large stretches of foreign DNA can be inserted into the Ad5 vector genome.
However, recent studies have revealed several disadvantages associated with the clinical use of Ad5 vectors. One disadvantage is the high prevalence of adult humans (450%) who produce neutralizing antibodies to Ad5. 3, 4 Pre-existing neutralizing antibodies prevent Ad vectors from transducing cells in vivo. 5 Furthermore, Ad vector preimmunization in mice has been demonstrated to significantly increase vectormediated liver toxicity on re-exposure. 6 Therefore, preexisting immunity to Ad5 vectors greatly hampers the in vivo application of Ad5 vectors. Inefficient transduction with Ad5 vectors of cells lacking expression of a primary receptor for Ad5, coxsackievirus and adenovirus receptor (CAR), is also highly problematic. Several important target cells for gene therapy, including hematopoietic stem cells, 7 dendritic cells (DCs) 8 and malignant tumor cells, 9 express low levels of CAR. To overcome these drawbacks of Ad5 vectors, several groups (including ours) have developed Ad vectors composed of other human Ad serotypes, such as Ad serotype 7a, 10 11 4, 11 and 35, 12-15 and Ads of animal origin, such as chimpanzee, 16 bovine, 17 mouse 18 and ovine. 19 Among these non-Ad5 vectors, those composed of human Ad11 and Ad35, which belong to subgroup B, are highly promising as gene transfer vectors for the following reasons. First, Ad11 and Ad35 are serotypes least neutralized by serum from healthy human blood donors: less than 20% of serum samples are positive for anti-Ad11 and -Ad35 neutralizing antibodies. 14 Second, human subgroup B Ads, including Ad11 and Ad35, recognize human CD46 (membrane cofactor protein) as a cellular receptor, 20, 21 although Ads belonging to subgroups A, C, D, E and F use CAR as a primary receptor. CD46 is a single-chain type I transmembrane glycoprotein that is ubiquitously expressed in all cells (except erythrocytes) in humans, suggesting that human sub-group B Ads can infect almost all human cell types, regardless of CAR expression. We previously demonstrated that Ad35 vectors show broad tropism toward human cells, 12, 13, 22 including CAR-negative cells, because of the ubiquitous expression of CD46. Furthermore, CD46 expression is highly upregulated in human malignant tumor cells, 23, 24 suggesting that these cells would be suitable targets for Ad35 vector-mediated transduction.
Adenovirus serotype 35 vectors exhibit efficient transduction in a variety of human cells in vitro. In contrast, systemic administration of Ad35 vectors into mice mediates low levels of transduction efficiencies in organs. 13, 14 The refractoriness of mice to Ad35 vectors would be owing to the expression pattern of CD46 in this host. Whereas CD46 is ubiquitously expressed in humans, expression of mouse CD46 is limited to the testes. In addition, mouse and human CD46 s are only 46% similar. 25 These differences indicate that the conventional mouse is not a suitable small animal model for characterization of Ad35 vector-mediated in vivo transduction. A small animal model in which the transduction properties of Ad35 vectors can be characterized appropriately is essential to estimate the efficiency of Ad35 vector-mediated transduction in humans.
In the present study, to evaluate the in vivo transduction properties of Ad35 vectors in an animal model that ubiquitously expresses CD46 (as do humans), we administered Ad35 vectors intravenously and intraperitoneally into homozygous and hemizygous human CD46-transgenic (CD46TG) mice, which have a human CD46 gene inserted into the mouse genome. Our results indicate that CD46 acts as an attachment receptor for Ad35 after in vivo administration, but the transduction efficiencies in organs were lower than we had expected.
First, Western blot analysis was performed to examine human CD46 expression levels in the organs of homozygous and hemizygous CD46TG mice. As shown in Figure 1 , human CD46 was ubiquitously expressed in all organs examined of homozygous and hemizygous CD46TG mice. In particular, amounts of CD46 were higher in the liver, spleen, lung and kidney than in other organs. CD46 expression patterns in CD46TG mice mimicked those observed in humans, which were reported previously, 26 and homozygous CD46TG mice expressed CD46 more abundantly than hemizygous mice. CD46 expression in the liver, spleen and diaphragm of homozygous mice was 3.2, 3.7 and 3.2 times that, respectively, in these organs of the hemizygous mice. We also confirmed that human CD46 expression levels in the primary hepatocytes, splenocytes and thymocytes of the homozygous mice were similar to, or lower than, those in human cultured cell lines (human hepatoma and leukemia lines; data not shown). Flow cytometric and Western blotting analysis failed to detect CD46 expression in the erythrocytes of our CD46TG mice (data not shown), although detectable levels of CD46 were expressed in the erythrocytes of some CD46TG mice lines used in other studies. 27, 28 Next, we performed in vitro transduction of an Ad35 vector into bone marrow-derived dendritic cells (mBM-DC) and peritoneal macrophages prepared from CD46TG and wild-type mice. Recently, the potential utility of Ad35 vectors as vaccine vectors has been proposed, 29, 30 and DC and macrophages are considered to be ideal targets for immunotherapy using Ad35 vector-based vaccines. Bone marrow-derived dendritic cells 31 and peritoneal macrophages 32 were prepared as Figure 1 Human CD46 expression in organs harvested from CD46TG mice. The protein samples were prepared from wild-type mice (0n), hemizygous CD46TG mice (1n) and homozygous CD46TG mice (2n). The molecular masses of marker proteins (kDa) and approximate positions of the two major isoforms of the CD46 proteins (BC and C isoforms) are indicated on the right. CD46TG mice were produced as follows. Spermatozoa were dispersed from the epididymis of mature (412 weeks old) B6D2F1 male mice into 400 ml of TYH medium 50 and were frozen in liquid nitrogen immediately after dilution with TYH medium to 1 Â 10 7 /ml. The bacterial artificial chromosome DNA carrying human CD46 (5 mg/ml in TE) (GenomeSystems Inc., St Louis, MO, USA) was added to thawed sperm after purification by using the Large-Construct Kit (Qiagen, Valencia, CA, USA). The mixture was incubated for 5 min at room temperature and then diluted with 9 volumes of 12% PVP-HCZB. Metaphase II oocytes for microinjection were prepared from B6D2F1 female mice, as described previously. 51 These oocytes were maintained in potassium simplex optimized medium (kSOM) under mineral oil equilibrated in 5% (v/v) CO 2 in air at 371C until use. For microinjection, sperm heads were aspirated into a pipette attached to a piezoelectric pipettedriving unit, and a sperm head was injected into each oocyte, as described previously. 51 After injection, the eggs were incubated in kSOM until two-cell stage, and were transferred to ICR pseudopregnant foster mothers. CD46TG mice were detected among the pups born by using genomic PCR as described previously. 40 After backcrossing to the C57Bl6 background for more than five generations, homozygous CD46TG mice were obtained by mating hemizygous mice. Homozygous CD46TG mice were identified by mating CD46TG mice with wild-type mice. For Western blotting analysis, organs collected from wild-type mice (C57Bl6, female, 5 weeks old, obtained from Nippon SLC Co. Ltd, Shizuoka, Japan) and CD46TG mice (female, 5 weeks old) were homogenized in phosphate-buffered saline containing 1% Triton-X, 2 mM EGTA and proteinase inhibitor cocktail (1 mM PMSF, 1 mg/ml pepstatin and 1 mg/ml leupeptin). After centrifugation of the homogenates, the supernatants (7.5 mg protein per sample) underwent nonreducing sodium dodecyl sulfate-12.5% polyacrylamide gel electrophoresis, and the separated proteins were transferred to a nitrocellulose membrane. After blocking of nonspecific binding, CD46 was detected with anti-CD46 rabbit serum (1:5000; kindly provided by Dr T Seya, Hokkaido University, Japan), followed by incubation in the presence of peroxidase-labeled anti-rabbit antibody (1:6000). Signals on the membrane were visualized and analyzed as described previously.
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Ad35 vector-mediated transduction F Sakurai et al described previously. An Ad35 vector that expresses green fluorescence protein (GFP), Ad35GFP, was prepared by means of an improved in vitro ligation method 22, 33, 34 using 293-E1B cells as a packaging cell line. 293-E1B cells are stable transformants expressing Ad35E1B proteins, which were generated by transfection of pEF-Ad35E1B into 293 cells and after selection with G418 (Invitrogen, Carlsbad, CA, USA). pEF-Ad35E1B was constructed by insertion of the fragment of the Ad35 genome (bp 1911-3413), which contains the Ad35 E1B-55 K gene, into pEF/myc/nuc (Invitrogen). The plaqueforming unit (PFU)-to-particle ratios of Ad35GFP in 293-E1B cells was 1:66.
Flow cytometric analysis showed that mBM-DC from hemizygous and homozygous CD46TG mice express considerable amounts of human CD46 (Figure 2a ): 47% of the mBM-DC from hemizygous mice and 87% of those from homozygous mice were CD46-positive (% of M1-gated). Transduction experiments demonstrated that Ad35GFP mediated more efficient transduction in mBM-DC from CD46TG mice than from wild-type mice ( Figure 3a ). Ad35GFP at a dose of 3000 vector particles (VP)/cell successfully transduced about 42% of the mBM-DC from the hemizygous CD46TG mice and 83% of those from homozygous mice. In contrast, only 3.8% of the mBM-DC from wild-type mice were positive for GFP expression, a rate that is only slightly above background level. In addition, mean fluorescence intensity data revealed that the mBM-DC from CD46TG mice were more susceptible to Ad35 vector than those from wildtype mice. Similar results were obtained for peritoneal macrophages. Human CD46 was expressed in 20% of the peritoneal macrophages from hemizygous CD46TG mice and in 41% of those from homozygous animals ( Figure   2b ). Infection by Ad35GFP resulted in 10% GFP-positive macrophages from hemizygous CD46TG mice and in 20% GFP-positive macrophages among those from homozygous transgenic mice. In contrast, the macrophages from wild-type mice were refractory to Ad35 vector-mediated transduction (Figure 3b ). These results indicate that human CD46 expression greatly increases the transduction efficiency of Ad35 vector in mouse primary cells and that the in vitro transduction efficiency of Ad35 vector depends on CD46 expression density.
The refractoriness of mBM-DC and macrophages from wild-type mice also suggests inefficient interaction between the RGD motif in the penton base of Ad35 vector and av-integrins on the cells. The hypervariable RGD loop in the penton base of the Ad35 vector is supposed to be shorter than that of conventional Ad5 viruses because the RGD loop of Ad11 (55 amino acids), the sequence of which is identical to that of Ad35, is shorter than that of Ad2 (74 amino acids). 35 It suggests that av-integrins on the cell surface might be less easily accessible to the RGD motif in the penton bases of Ad35 between the RGD motif in the penton base and avintegrins, even in the absence of the primary receptor for Ad5, CAR. 36 Next, to assess the in vivo transduction properties of Ad35 vectors in CD46TG mice, we intravenously and intraperitoneally administered an Ad35 vector that expressed luciferase (Ad35L). Ad35L was prepared in the same way as Ad35GFP. The PFU-to-particle ratio of Ad35L in 293-E1B cells was 1:625. Intravenous administration of Ad35L to hemizygous and homozygous CD46TG mice increased the transduction efficiencies for the liver, lung and kidney over those in wild-type mice. In contrast, no apparent increase in luciferase production occurred in the spleen or thymus of CD46TG mice (Figure 4a ). There were no clear differences in the transduction efficiencies of Ad35 vectors between the homozygous and hemizygous mice, except in the case of liver.
In contrast, transduction efficiencies of Ad35L in the liver, spleen and kidney of CD46TG mice after intraperitoneal administration were much higher than those after intravenous administration (Figure 4b ). Intraperitoneal injection into homozygous mice led to transduction efficiencies in the liver and kidney that were 83 and 271 times that after intravenous administration, respectively. Furthermore, even larger differences in transduction efficiency occurred between CD46TG mice and wildtype mice after intraperitoneal injection. Luciferase production from the liver, kidney and diaphragm of homozygous mice was 536, 492 and 83 times, respectively, that of wild-type mice. Comparison of the homozygous and hemizygous mice demonstrated that after intraperitoneal administration of vector, the homozygous mice appeared to be more susceptible to Ad35 vectors. Transgene expression levels in the liver and diaphragm of homozygous mice were 6.8 and 5.5 times, respectively, those of the hemizygous mice. The increased transduction efficiencies in the homozygous mice are probably owing to their increased levels of CD46 expression (Figure 1 ). These results indicate that CD46TG mice are more susceptible to Ad35 vectors than wild-type mice. However, the transduction efficiencies of Ad35 vectors in CD46TG mice after both intraperitoneal and intravenous injection were much lower than those of conventional Ad5 vectors in wild-type mice. 13 Luciferase production in the liver and spleen by Ad35 vectors intravenously administered to homozygous CD46TG mice was approximately 20 000 and 57 times lower, respectively, than that from Ad5 vectors administered intravenously to wild-type mice at the same dose as for the Ad35 vector in the present study (Ad5 vectormediated luciferase expression levels in wild-type mice at a dose of 1.5 Â 10 10 VP/mouse after intravenous administration: liver, 2266 pg/mg protein; spleen, 0.893 pg/mg protein; kidney, 0.768 pg/mg protein; heart, 2.13 pg/mg protein; lung, 0.252 pg/mg protein). 13 Next, to compare the fate of Ad35 vectors after in vivo administration to wild-type versus CD46TG mice, we used real-time PCR at 48 h post-administration to measure the amounts of Ad35L genomic sequences that had accumulated in various organs. After intravenous administration to CD46TG mice, the vector DNA in the sampled organs of CD46TG mice (except for liver) exceeded that in those of wild-type mice (Figure 5a ). In addition, homozygous mice appeared to take up higher amounts of Ad35L than hemizygous mice. For example, Ad35 vector quantities in the spleen, which contained the most Ad35 vector DNA among the organs tested, of hemizygous and homozygous mice were 8 and 69 times, respectively, that in wild-type mice. In contrast, Ad35 vector DNA did not accumulate to high levels in the liver of CD46TG mice. Moreover, these quantities were similar, or slightly lower than, those in other organs of CD46TG mice, even though liver is well known to be a predominant organ for sequestration of Ad5 vectors administered intravenously to mice. 37, 38 After intraperitoneal injection, Ad35L was accumulated more efficiently in the liver, kidney, peritoneum Figure 4 Luciferase production in CD46TG and wild-type mice after intravenous and intraperitoneal administration of Ad35L. (a) Luciferase production after intravenous administration of the vector. (b) Luciferase production after intraperitoneal administration. Ad35L (1.5 Â 10 10 VP) was administered to wild-type mice (C57Bl6, 5 weeks old) and hemizygous (Hemi TG, 5-6 weeks old) and homozygous (Homo TG, 5-6 weeks old) CD46TG mice. After 48 h, the organs were harvested and homogenized as described previously, 53 and luciferase production was measured by a luminescence assay system (PicaGene 5500; Toyo Inki, Japan). The data are represented as mean7s.d. (n ¼ 4, intravenous administration; n ¼ 6, intraperitoneal administration).
Ad35 vector-mediated transduction F Sakurai et al and diaphragm of CD46TG mice than in those of wildtype mice (Figure 5b ). The quantities of vector DNA in the liver and kidney of homozygous CD46TG mice were 11 and 14 times, respectively, those of wild-type mice. Furthermore, Ad35 vector DNA tended to be accumulated more efficiently in the liver, spleen, peritoneum and diaphragm of the homozygous mice than in those of the hemizygous mice. In addition, low levels of viral DNA were detected in the lung and heart, which are not directly accessible to intraperitoneally injected Ad35L from the injection point, with no significant difference between CD46TG mice and wild-type mice in the amounts that were detected. The data on the in vivo transduction efficiencies and viral DNA accumulation indicate that Ad35 vectors administered in vivo use human CD46 in CD46TG mice. In both intravenous and intraperitoneal dosing experiments, the total amounts of Ad35 vector DNA recovered from wild-type mice were lower than those from CD46TG mice. The decreased recovery of Ad35 vector DNA from wild-type mice could be due to its degradation in phagocytic cells, such as liver Kupffer cells. We speculate that the absence of human CD46 expression in organs results in decreased infection of the organs and increased uptake of Ad35 vector by phagocytic cells, leading to degradation of Ad35 vector DNA. In the previous study, we demonstrated that Ad35 vectors predominantly were taken up by liver nonparenchymal cells (endothelial and Kupffer cells) after intravenous administration in wild-type mice, and that the internalized Ad35 vector DNA was degraded rapidly. 13 Finally, to examine the types of cells that Ad35 vectors transduce in CD46TG mice, we performed X-gal staining of the peritoneal organs after intraperitoneal administration of Ad35LacZ, an Ad35 vector expressing b-galactosidase (dose, 7.5 Â 10 10 VP/mouse). The vector was prepared by means of an improved in vitro ligation method 22, 33, 34 using pAdMS18 and pHMCMV6-LacZ. pAdMS18 was constructed by ligating oligonucleotides encoding I-CeuI/SwaI/PI-SceI into the PacI site of pFS2-Ad35-7.
12 pHMCMV6-LacZ was generated by cloning the Escherichia coli b-galactosidase gene derived from pCMVb (Clontech, Palo Alto, CA, USA) into the multicloning site of pHMCMV6. 34 The PFU-to-particle ratio of Ad35LacZ in 293-E1B cells was 1:315.
The peritoneal organs (liver, kidney and peritoneum) were efficiently transduced with Ad35LacZ (Figure 6a-f) . However, X-gal staining of liver and kidney sections revealed that mainly the mesothelial cells on the surface of the liver and kidney were transduced; few deeper cells were transduced (Figure 6g-j) . These results indicate that after injection, Ad35 vectors directly access the mesothelial cells of these organs, leading to efficient transduction.
In the present study, we assessed the in vitro and in vivo transduction properties of Ad35 vectors by using homozygous and hemizygous human CD46TG mice, a small animal model in which human CD46 is expressed with human-like tissue specificity. Human CD46 serves as a cellular receptor for not only subgroup B Ads but also several human pathogens, including measles virus, human herpes virus 6 and two types of bacteria. 39 Therefore, CD46TG mice already have been used in several studies, which have reported that replication of the pathogens and inflammatory responses occur in CD46TG mice after exposure to the pathogens, demonstrating the utility of CD46TG mice as animal models (note that for study of measles virus, the alpha/beta-interferon receptor gene is usually knocked out with insertion of the human CD46 gene). 28, 40, 41 In addition, in most of the CD46TG mice lines used in these studies, including in our present study, expression of human CD46 is driven by the human CD46 promoter, not the promoter of a ubiquitously expressed gene, leading to a pattern of CD46 expression similar to that in humans. 27, 28, 40 This conservation of the expression pattern is another advantage of using CD46TG mice as an animal model. 10 VP) was administered to wild-type mice (C57Bl6, 5 weeks old) and hemizygous (Hemi TG, 5-6 weeks old) and homozygous (Homo TG, 5-6 weeks old) CD46TG mice. After 48 h, the organs were harvested, and total DNA including viral DNA was extracted from the tissues after proteinase K digestion, and 25 ng samples of total DNA were subjected to quantitative real-time PCR, as described previously. 22 The data are represented as mean7s.d. (n ¼ 4).
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In vivo transduction experiments using CD46TG mice showed that Ad35 vectors mediated higher transduction efficiencies in CD46TG mice than wild-type mice, indicating that Ad35 vectors recognize human CD46 as an attachment receptor on in vivo application. However, the transduction efficiencies of Ad35 vectors in CD46TG mice were much lower than expected. Addition of human CD46 expression to mouse primary cells greatly enhanced Ad35 vector-mediated transduction (Figure 3) . Our previous study demonstrated that the transduction activities of Ad5 and Ad35 vectors were nearly equivalent in human cultured cell lines, 13 which express high levels of CD46. These results suggest that, in cells expressing sufficient CD46, the transduction efficiencies of Ad35 vectors could be similar to those of Ad5 vectors. Therefore, we had expected that the transduction efficiencies of Ad35 vectors in CD46TG mice would greatly increase to levels comparable to those of Ad5 vectors. However, the transduction efficiencies of Ad35 vectors in the organs of homozygous CD46TG mice after intravenous administration were approximately 20-to 20 000-fold lower than those of conventional Ad5 vectors at the same dose (1.5 Â 10 10 VP/mouse) in wild-type mice. 13 Why the in vivo transduction efficiencies of Ad35 vectors in CD46TG mice were lower than expected remains to be clarified. One possibility is that Ad35 vectors administered to CD46TG mice cannot access the human CD46 that is expressed on the cells. Human CD46 primarily is expressed on the basolateral surfaces of polarized epithelial cells, 42, 43 and measles virus preferentially infects cells from their basolateral, rather than apical, sides. 44 Anatomical barriers such as the tightness between the basal membrane and extracellular matrix might impair the access of Ad35 vectors to the human CD46 on the basolateral cell surface. Another possibility is that an unidentified receptor or co-receptor for Ad35 is expressed in humans but not in CD46TG mice. Segerman et al. 45 suggest that there are two different receptors in human cells for subgroup B Ads. Interaction between Ad35 vectors and blood components (blood cells or serum proteins) might also inhibit Ad35 vector-mediated transduction after intravenous administration. In particular, the soluble form of human CD46, which is found in normal human serum, 46 might block infection by Ad35 vectors. However, preincubation of Ad35 vectors with serum or blood cells recovered from CD46TG mice did not reduce the transduction efficiencies of Ad35 vectors in vitro (data not shown). Further evaluation is necessary to clarify whether studies using CD46TG mice appropriately evaluate the transduction properties of Ad35 vectors. Currently, we are examining the transduction properties of Ad35 vectors in non-human primates, which express CD46 in all organs. The findings should greatly help us to understand characteristics of Ad35 vector-mediated transduction, including the validity and utility of CD46TG mice as model animals for Ad35 vectors.
The fiber shaft of Ad35 lacks the KKTK (Lys-Lys-ThrLys) motif, which is located in the fiber shaft of Ad5 and is considered to bind to heparan sulfate, 47 and its absence may partly explain the lower transduction efficiencies of Ad35 vectors than Ad5 vectors. Smith et al. 47 demonstrated that amino-acid substitution of the KKTK motif dramatically decreased the transduction efficiencies of Ad5 vectors in the mouse liver, whereas ablation of CARand integrin-binding sites did not significantly reduce the transduction efficiency of Ad5 vectors in the liver; these findings indicate a potential role for heparan sulfate binding in Ad5 vector-mediated liver transduction. In addition, we reported that replacement of the Ad5 fiber shaft with the Ad35 shaft, in addition to the ablation of CAR and integrin binding, decreases Ad5 transduction efficiencies in the liver. 48 Heparan sulfate 
peritoneum, (h) liver and (j) kidney sections from mock-infected homo TG mice. Ad35LacZ was injected intraperitoneally into homozygous CD46TG mice at a dose of 7.5 Â 10 10 VP/mouse. At 2 days postadministration, the organs were recovered after perfusion with 0.5% glutaraldehyde solution and then fixed and stained as described previously 54 by using 0.5% glutaraldehyde instead of 4% paraformaldehyde. For X-gal staining of liver and kidney, 10 mm sections were cut, fixed with 0.5% glutaraldehyde, and stained as described previously.
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Ad35 vector-mediated transduction F Sakurai et al binding may be a more crucial determinant for Ad vectormediated in vivo transduction of mice, especially in the liver, than binding to primary receptors (CAR for Ad5 and CD46 for Ad35), irrespective of Ad5 or Ad35 vectors.
Homozygous CD46TG mice, which express CD46 more abundantly than hemizygous CD46TG mice, seem to be more susceptible to Ad35 vectors than hemizygous mice (Figure 4) . Our in vitro transduction experiments that used primary cells from CD46TG mice also demonstrated that mBM-DC and peritoneal macrophages derived from wild-type mice were refractory to Ad35 vectors, but high-level CD46 expression in cells from CD46TG mice increased the transduction efficiencies of Ad35 vectors (Figure 3) . Together, these results indicate that CD46 expression levels are a crucial factor in Ad35 vector-mediated transduction. Anderson et al. 49 reported a similar result, in which the transduction efficiencies of the chimeric Ad5F35 vector, which is an Ad5-based vector containing an Ad35 fiber shaft and knob, increased progressively with CD46 expression density in a panel of CHO cells stably expressing CD46. 49 Together, these findings suggest that Ad35 vectors can be a potent and selective platform for transduction into tumor cells expressing high levels of CD46, because human malignant tumor cells (including primary tumor cells) express CD46 more abundantly than nontransformed human cells. 23, 24 Engineered measles viruses, which enter cells efficiently via CD46, exhibit selective oncolytic activity by exploiting the difference in CD46 expression levels between ovarian cancer cells and nontransformed cells. 23 Transduction efficiencies of intraperitoneal-administered Ad35 vectors were 410-fold higher in homozygous CD46TG mice than in wild-type mice (Figure 4 ). In particular, peritoneal organs, such as the liver, kidney, peritoneal wall and diaphragm, were transduced efficiently. X-gal staining experiments demonstrated that efficient transduction occurred mainly in the mesothelial cells of the liver and kidney ( Figure 6 ). In contrast, noteworthy luciferase production after intraperitoneal administration of Ad35 vector was not detected in the lung or heart, which are distant from the peritoneal cavity. Few LacZ-positive cells were found in the interior of the liver and kidney. These results indicate that after intraperitoneal injection, a portion of the Ad35 vector dose efficiently infects the mesothelia of tissues via CD46 on the surface of the organ, leading to efficient transduction. Another fraction of the dose, which is probably exuded into the bloodstream from the peritoneal cavity, likely poorly transduces the tissues of CD46TG mice. Using quantitative real-time PCR, we confirmed that Ad35 vector DNA was present in the blood after intraperitoneal injection (data not shown).
In summary, we demonstrated that Ad35 vectors used the human CD46 expressed in CD46TG mice as an attachment receptor after in vivo administration. CD46TG mice are more susceptible to Ad35 vector-mediated transduction than wild-type mice, but the transduction efficiencies of Ad35 vectors in CD46TG mice were much lower than those of conventional Ad5 vectors. 13 As a next step, evaluation of Ad35 vector-mediated transduction in non-human primates, which ubiquitously express CD46 (as do humans), is necessary to assess the validity and utility of CD46TG mice as small animal models for Ad35 vectors.
